Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2017 | Pages:
77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2017 Summary Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Beta-secretase 1 (BACE1) is an enzyme that in humans is encoded by the BACE1 gene. It is responsible for the proteolytic processing of the amyloid precursor protein (APP). It cleaves at the N-terminus of the A-beta peptide sequence of APP. This leads to the generation and extracellular release of beta-cleaved soluble APP and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase. Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 1 and 12 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 6 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Alzheimer's Disease, Dementia Associated With Alzheimer's Disease, Mild Cognitive Impairment and Neurodegenerative Diseases. The latest report Beta Secretase 1 - Pipeline Review,, outlays comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development with respective active and dormant or discontinued projects. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)targeted therapeutics and enlists all their major and minor projects - The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Overview Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Companies Involved in Therapeutics Development Allergan Plc Amgen Inc AstraZeneca Plc Bristol-Myers Squibb Company Eisai Co Ltd Eli Lilly and Company Genentech Inc H. Lundbeck A/S Johnson & Johnson Merck & Co Inc Novartis AG Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Drug Profiles AMG-8718 - Drug Profile Product Description Mechanism Of Action R&D Progress AVCRI-104P3 - Drug Profile Product Description Mechanism Of Action R&D Progress AVCRI-175P1 - Drug Profile Product Description Mechanism Of Action R&D Progress AZ-4217 - Drug Profile Product Description Mechanism Of Action R&D Progress CNP-520 - Drug Profile Product Description Mechanism Of Action R&D Progress elenbecestat - Drug Profile Product Description Mechanism Of Action R&D Progress ER-901356 - Drug Profile Product Description Mechanism Of Action R&D Progress GNE-892 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-54861911 - Drug Profile Product Description Mechanism Of Action R&D Progress lanabecestat camsylate - Drug Profile Product Description Mechanism Of Action R&D Progress LuAF-66432 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-2811376 + LY-3002813 - Drug Profile Product Description Mechanism Of Action R&D Progress LY-3202626 - Drug Profile Product Description Mechanism Of Action R&D Progress Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit BACE 1 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile Product Description Mechanism Of Action R&D Progress TAK-070 - Drug Profile Product Description Mechanism Of Action R&D Progress verubecestat - Drug Profile Product Description Mechanism Of Action R&D Progress VTP-36951 - Drug Profile Product Description Mechanism Of Action R&D Progress Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Dormant Products Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Discontinued Products Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Product Development Milestones Featured News & Press Releases Mar 29, 2017: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor Elenbecestat In Early Alzheimer's Disease In Japan Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy Dec 12, 2016: Eisai Presents Latest Data On Bace Inhibitor Elenbecestat (E2609) At 9Th Clinical Trials On Alzheimer's Disease Nov 18, 2016: U.S. FDA Grants Fast Track Designation For The Development Of Eisai's Bace Inhibitor E2609 For Early Alzheimer'S Disease Nov 02, 2016: Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine Oct 31, 2016: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor E2609 In Early Alzheimer's Disease Aug 22, 2016: Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer's Disease to Phase III Jun 14, 2016: New Alzheimers Study Aimed at Preventing or Delaying Symptoms Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer's disease Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 "EPOCH" Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer's Disease Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer's disease May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimer's Disease Therapy, MK-8931 Jul 14, 2013: Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer's Disease Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Allergan Plc, H1 2017 Pipeline by Amgen Inc, H1 2017 Pipeline by AstraZeneca Plc, H1 2017 Pipeline by Bristol-Myers Squibb Company, H1 2017 Pipeline by Eisai Co Ltd, H1 2017 Pipeline by Eli Lilly and Company, H1 2017 Pipeline by Genentech Inc, H1 2017 Pipeline by H. Lundbeck A/S, H1 2017 Pipeline by Johnson & Johnson, H1 2017 Pipeline by Merck & Co Inc, H1 2017 Pipeline by Novartis AG, H1 2017 Dormant Projects, H1 2017 Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
